Management Of Giant Dysgerminoma Wıth Paraaortic Lymph Node Involvement

Abstract

Dysgerminomas account for %1-3 of all ovarian tumors and up to %30-40 off all germ cell malignancies. They tend to be diagnosed at an average of 22 years of age. A 24 year old patient with a complaint of abdominal distention was diagnosed wih dysgerminoma mass diameter of approximately 30 cm originating from the right ovary; in addition, the presence of metastatic paraaortic lymph nodes was noted during laparatomy. Right salpingooopherectomy, pelvic paraaortic lymph node dissection, left ovarian excisional biopsy, appendectomy and omentectomy was performed. The pathology result reported the tumor to be FIGO Stage IIIc. Post-operative chemotherapy treatment was started. We wanted to discuss the treatment and management of dysgerminoma with assisting paraaortic lymph nodes via the patient mentioned above accompanied by literature.

Keywords

• Giant dysgerminomas,metastatic paraaortic lymph nodes,germ cell malignancies

Paraaortik Lenf Nodu Tutulumu İle Seyreden Dev Disgerminom Yönetimi

Abstract

Disgerminomlar, over kanserlerinin %1-3 ünü ve tüm germ hücreli over tümörlerinin %30-40 ını oluştururlar. Ortalama görülme yaşı 22 dir. 24 yaşında karında şişlik şikayeti olan hastada sağ over kaynaklı paraaortik lenf nodu tutulumu olan yaklaşık 30 cm çapında dev disgerminom tespit edildi. Hastaya sağ salpingingoooferektomi, pelvik ve paraoartik lenf nodu diseksiyonu, sol over biyopsisi, apendektomi, omentektomi yapıldı. Patoloji sonucu FIGO Evre IIIc disgerminom olarak geldi. Hastaya kemoterapi tedavisine başlanıldı. Bu olgu ile paraaortik lenf nodu tutulumu ile seyreden disgerminomların tedavi ve yönetimini literatür eşliğinde sunmak istedik.

Keywords

• Dev disgerminom,paraaortik lenf nodu metastazı,germ hücreli tümör

References

1. 1. Berek JS, Hacker NF. Overian and fallopian tubes. In: Haskell CM, ED. Cancer Treatment. 4th ed. Philadelphia: WB Saunders, 1995
2. 2. Kurman RJ, Scardino PT, Waldmann TA, Melntire KK, Javadpour N, Norris DJ, et al. Malignant germ cell tumors of the ovary and testis: an immunologic study of cases. Ann Clin Lab Sci 1979; 462-6
3. 3. Tanios Bekaii- Saab, M. D:, Lawrence H Einhorn, M.D. , Stephen D. Williams, M.D. Late relapse of overian dysgerminoma: case report and literatür review. Indiana University Cancer Center. Gynecol Oncol 1999, 72, 111-112
4. 4. Zaloudek CJ, Tavassoli FA, Norris DJ. Dysgerminoma with syncytiotrophoblastik giant cells: a histologically and clinically distinctive subtype of dysgerminoma. Am J Surg Pathol 1981; 5:361-7
5. 5. La Polla JP, Bende J, Vigloitti AP et all. Dysgerminoma at the ovary. Obstet Gynecol 1987. 69: 859.
6. 6. Zhang R, Hong W, Li S. Dysgerminoma of the ovary: a clinical retrospektive analysis of 60 cases : Zhonghua Fu Chan Ke Za Zhi 1995 Sep;30(9):550-2
7. 7. Bjorkholm E, Lundell M, Gyftodimos A, Silfversward C Dysgerminoma. The Radiumhemmet series 1927-1984. Cancer 1990 Jan 1;65(1):38-44
8. 8. Zhang R, Hong W, Li S. Dysgerminoma of the ovary: a clinical retrospective analysis of 60 cases ; Zhonghua Fu Chan Ke Za Zhi 1995 Sep;30(9):550-2

9. 9. Mount PM, Norris HJ. Advances in germ cell tumors of the ovary. In: Dallenback- Hellweg Sixth edition. Ovarian Tumoren,Springer, Berlin 1982;83-94.
10. 10.Russell H, Presley MD, Howard G. Muntz, Stephan Falkenberry, Laurel W Rice. Serum lactic dehydrogenase as a tumor marker in dysgerminoma. Gynecologic Oncology, Volume 44, Ýssue 3,March 1992, Sayfa :281- 283.
11. 11.Ayhan A, Bildirici I, Günalp S, Yüce K. Pure dysgerminoma of the ovary: a review of 45 well staged cases. : Eur J Gynaecol Oncol 2000;21(1):98-101
12. 12.Santoni R, Cionini L, D'Elia F, Scarselli GF, Branconi f, Savino L. Dysgerminoma of the ovary: a report on 29 patients. Clin Radiol 1987 Mar;38(2):203-6